抄録
Out of three free-living populations, 320 subjects over 40 years of age were randomly selected and divided into two groups: the group treated daily with 0.75mg of an anabolic steriod, ethylnandrol, and the control group on placebo (Table 1). Their physical status, ocular fundus, ECG, urine and, on fasting blood sample, serum cholesterol, triglyceride and GOT were examined once or twice a year for five years. At every follow-up observation, the possible episode of ischemic disease and the side effects of the treatment were examined. At the 48th month examination, plasma fibrinogen and euglobulin lysis time were measured for the both groups.
The mean cholesterol levels of the treatment group were significantly lower than those of the control group throughout the observation period, although both groups had a seasonal fluctuation in cholesterol level high in summer and low in winter. The mean triglycerides were also lower in the treatment group (Fig. 1). Hypertension, defined as blood pressure above 160mmHg systolic and 95mmHg diastolic, decreased in the prevalence in both groups, and no difference is seen between the two groups. The mean concentrations of plasma fibrinogen were 266±58mg% for the treatment group, and 243±58mg% for the control group, the difference between the two being not statistically significant. The mean euglobulin lysis time was 342±45min. for the treatment group, 373±50min. for the control group. The euglobilin lysis time was significantly shortened in the treatment group. (p<0.05).
The primary episode of 6 cerebral infarctions occurred in the treatment group, while those of 6 cerebral infarctions and 2 myocardial infarctions in the control group. No death occurred in the treatment group, while 2 out of 6 cerebral infarctions died within one month of the onset of the disease in the control group (Fig. 2).
The three major risk factors for the cerebral infarction were age, hypercholesterolemia, and systolic hypertension. The risk factors for myocardial infarction were not yet evaluted since the numbers of patients were still too small.
No such side effects of long term administration of ethylnandrol as maleness, body weight gain, glucose tolerance and liver dysfuncton were seen in the subjects taking ethylnandrol for 5 years.
